NOVO-NORDISK A/S-SPONS ADR (NVO)
US6701002056 - ADR
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (12/6/2024, 8:04:50 PM)
After market: 110.74 -0.03 (-0.03%)110.77
+1.95 (+1.79%)
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880
P: 4544448888
CEO: Lars Fruergaard Jorgensen
Employees: 71880
Website: https://www.novonordisk.com/
NVO News
2 hours ago - The Motley FoolCould Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.17 hours ago - Investor's Business DailyStock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly ReviewSalesforce and mostly positive tech earnings buoyed the major indexes.
a day ago - ChartmillDespite its growth, NYSE:NVO remains within the realm of affordability.NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank.
2 days ago - Investor's Business DailyThe Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion MarketAn age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
2 days ago - The Motley FoolThis Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.
3 days ago - Yahoo FinanceZepbound tops Wegovy for weight loss in Eli Lilly studyShares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss.
NVO Twits
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
